Ifosfamide-containing regimens for treating patients with osteosarcomas.
Asian Pac J Cancer Prev
; 15(22): 9763-6, 2014.
Article
em En
| MEDLINE
| ID: mdl-25520101
ABSTRACT
BACKGROUND:
This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma.METHODS:
Clinical studies evaluating the efficacy and safety of Ifosfamide-containing regimen on response and safety for patients with osteosarcoma were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated.RESULTS:
When ifosfamide-containing regimens were evaluated, 4 clinical studies which including 134 patients with osteosarcoma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 44.8% (60/134) in ifosfamide-containing regimens. Major adverse effects were neutropenia, leukopenia, and fatigue inIfosfamide-containing regimens; No treatment related death occurred in cantharidin combined regimens.CONCLUSION:
This systemic analysis suggests that ifosfamide-containing regimens are associated with good response rate and acceptable toxicity in treating patients with osteosarcoma, but this result should be confirmed by randomized clinical trials.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ósseas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Osteossarcoma
/
Recidiva Local de Neoplasia
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Humans
Idioma:
En
Revista:
Asian Pac J Cancer Prev
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2014
Tipo de documento:
Article